Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Eliciting broadly protective antibody responses against influenza.

Kirchenbaum GA, Ross TM.

Curr Opin Immunol. 2014 Jun;28:71-6. doi: 10.1016/j.coi.2014.02.005. Epub 2014 Mar 12. Review.

PMID:
24632083
2.

Efficacy of live attenuated influenza vaccine in children against influenza B viruses by lineage and antigenic similarity.

Belshe RB, Coelingh K, Ambrose CS, Woo JC, Wu X.

Vaccine. 2010 Feb 25;28(9):2149-56. doi: 10.1016/j.vaccine.2009.11.068. Epub 2009 Dec 8.

PMID:
20003926
3.

Protective immunity based on the conserved hemagglutinin stalk domain and its prospects for universal influenza vaccine development.

Khanna M, Sharma S, Kumar B, Rajput R.

Biomed Res Int. 2014;2014:546274. doi: 10.1155/2014/546274. Epub 2014 May 25. Review.

4.

Antibody responses against influenza A(H1N1)pdm09 virus after sequential vaccination with pandemic and seasonal influenza vaccines in Finnish healthcare professionals.

Strengell M, Ikonen N, Ziegler T, Kantele A, Anttila VJ, Julkunen I.

Influenza Other Respir Viruses. 2013 May;7(3):431-8. doi: 10.1111/j.1750-2659.2012.00415.x. Epub 2012 Aug 23.

5.

Heterosubtypic antibody response elicited with seasonal influenza vaccine correlates partial protection against highly pathogenic H5N1 virus.

Ding H, Tsai C, Zhou F, Buchy P, Deubel V, Zhou P.

PLoS One. 2011 Mar 25;6(3):e17821. doi: 10.1371/journal.pone.0017821.

6.

Immune responses to influenza virus infection.

Kreijtz JH, Fouchier RA, Rimmelzwaan GF.

Virus Res. 2011 Dec;162(1-2):19-30. doi: 10.1016/j.virusres.2011.09.022. Epub 2011 Sep 22. Review.

PMID:
21963677
7.

Evolving strategies for the prevention of influenza infection: potential for multistrain targeting.

Livingston BD, Higgins D, Van Nest G.

BioDrugs. 2006;20(6):335-40.

PMID:
17176120
8.

Antibody breadth and protective efficacy are increased by vaccination with computationally optimized hemagglutinin but not with polyvalent hemagglutinin-based H5N1 virus-like particle vaccines.

Giles BM, Bissel SJ, Dealmeida DR, Wiley CA, Ross TM.

Clin Vaccine Immunol. 2012 Feb;19(2):128-39. doi: 10.1128/CVI.05533-11. Epub 2011 Dec 21.

9.
10.

Pediatric influenza vaccination: understanding the T-cell response.

Bodewes R, Fraaij PL, Osterhaus AD, Rimmelzwaan GF.

Expert Rev Vaccines. 2012 Aug;11(8):963-71. Review.

PMID:
23002977
11.

Keeping the memory of influenza viruses.

Combadière B, Sibéril S, Duffy D.

Pathol Biol (Paris). 2010 Apr;58(2):e79-86. doi: 10.1016/j.patbio.2010.01.010. Epub 2010 Mar 19. Review.

PMID:
20303671
12.

Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus.

Khurana S, Chearwae W, Castellino F, Manischewitz J, King LR, Honorkiewicz A, Rock MT, Edwards KM, Del Giudice G, Rappuoli R, Golding H.

Sci Transl Med. 2010 Jan 20;2(15):15ra5. doi: 10.1126/scitranslmed.3000624.

13.

Learning from the 2009 H1N1 pandemic: prospects for more broadly effective influenza vaccines.

Settembre EC, Dormitzer PR, Rappuoli R.

J Mol Cell Biol. 2011 Jun;3(3):144-6. doi: 10.1093/jmcb/mjq046. Epub 2011 Mar 23.

PMID:
21430014
14.

Prevention of influenza virus shedding and protection from lethal H1N1 challenge using a consensus 2009 H1N1 HA and NA adenovirus vector vaccine.

Jones FR, Gabitzsch ES, Xu Y, Balint JP, Borisevich V, Smith J, Smith J, Peng BH, Walker A, Salazar M, Paessler S.

Vaccine. 2011 Sep 16;29(40):7020-6. doi: 10.1016/j.vaccine.2011.07.073. Epub 2011 Aug 5.

15.

Prospects for an influenza vaccine that induces cross-protective cytotoxic T lymphocytes.

Brown LE, Kelso A.

Immunol Cell Biol. 2009 May-Jun;87(4):300-8. doi: 10.1038/icb.2009.16. Epub 2009 Mar 24. Review.

PMID:
19308073
16.

Prospects for universal influenza virus vaccine.

Gerhard W, Mozdzanowska K, Zharikova D.

Emerg Infect Dis. 2006 Apr;12(4):569-74.

17.

Co-administration of certain DNA vaccine combinations expressing different H5N1 influenza virus antigens can be beneficial or detrimental to immune protection.

Patel A, Gray M, Li Y, Kobasa D, Yao X, Kobinger GP.

Vaccine. 2012 Jan 11;30(3):626-36. doi: 10.1016/j.vaccine.2011.11.017. Epub 2011 Nov 23.

PMID:
22119588
18.

Purified viral neuraminidase vaccine to control influenza.

Arora DJ.

Can Med Assoc J. 1979 Dec 22;121(12):1575-9. Review.

19.

Heterosubtypic immunity against human influenza A viruses, including recently emerged avian H5 and H9 viruses, induced by FLU-ISCOM vaccine in mice requires both cytotoxic T-lymphocyte and macrophage function.

Sambhara S, Kurichh A, Miranda R, Tumpey T, Rowe T, Renshaw M, Arpino R, Tamane A, Kandil A, James O, Underdown B, Klein M, Katz J, Burt D.

Cell Immunol. 2001 Aug 1;211(2):143-53.

PMID:
11591118
20.

Reduced antibody responses to the pandemic (H1N1) 2009 vaccine after recent seasonal influenza vaccination.

Choi YS, Baek YH, Kang W, Nam SJ, Lee J, You S, Chang DY, Youn JC, Choi YK, Shin EC.

Clin Vaccine Immunol. 2011 Sep;18(9):1519-23. doi: 10.1128/CVI.05053-11. Epub 2011 Aug 3.

Supplemental Content

Support Center